Articles tagged with Parkinsons Disease
The study reveals that protein misfolding in the brain can be toxic, even before visible amyloid fibrils form. Researchers used super-resolution microscopy to observe how alpha-synuclein proteins interact and found that excess soluble protein can cause toxic effects.
A study published in Neurobiology of Disease found that neurons with a defective DJ1 gene experience oxidative stress and immune response imbalances due to disrupted glutamine and serine metabolism. This knowledge could lead to novel therapeutic strategies by targeting affected metabolic pathways.
A study using molecular simulations suggests that polyunsaturated lipids can alter the binding rate of dopamine and adenosine receptors, affecting cell function in neurodegenerative diseases. This discovery could lead to new therapeutic pathways for regulating receptor binding.
Seven major pharmaceutical companies have signed up to a groundbreaking Parkinson's consortium aimed at accelerating the development of safe and effective therapies. The consortium will share data, expertise, and resources with leading academics and industry members to promote and develop new treatments for Parkinson's.
A stem cell study published in Stem Cell Reports has discovered that the GBA1 mutation creates problems with protein processing and recycling in cells, leading to an accumulation of alpha-synuclein. This excess protein is released into the brain, contributing to Parkinson's spread and symptoms.
A study published in The Journal of Physiology found that neurons in the thalamus can be conditioned to respond to placebos in Parkinson's patients. When apomorphine was administered before a placebo, it increased thalamic neuronal activity and clinical improvement. The response lasted up to 24 hours.
A new study published in PLOS Medicine found that Parkinson's patients experience a higher risk of injurious falls and hip fractures up to 30 years before diagnosis. This suggests early signs of balance issues may be an indicator of the disease.
Research found patients with PD were more likely to have had a hip fracture or injurious fall in the years preceding their diagnosis. Individuals who suffered injurious falls were also at higher risk of being diagnosed with PD in following years.
Researchers at Mayo Clinic have developed a saliva gland test that can detect early Parkinson's disease. The test involves taking a biopsy of the submandibular gland, which has been shown to be effective in detecting the abnormal protein associated with the disease in 14 out of 19 patients.
Researchers at EPFL create cellular and mouse models that accurately reproduce the evolution of Parkinson's disease, using insights into protein clumps called Lewy bodies. The new models can propel research and drug development, offering a powerful tool for rapid screening of molecular pathways involved in the disease.
Researchers at Gladstone Institutes uncover a neural circuit that controls walking and find a new target for treating Parkinson's disease. Dopamine depletion disrupts movement by miscommunicating between the basal ganglia and thalamus, leading to an imbalance between go and stop pathways.
Scientists have identified a protein called Tet3FL that acts as a 'guardian' against neurodegenerative diseases like Parkinson's. Tet3FL removes molecules called methyl groups from specific genes, keeping them active and maintaining cellular 'trash removal' processes.
A large clinical trial conducted on patients with mild to moderate Parkinson disease found no clinically meaningful benefits from physiotherapy and occupational therapy. The study included over 762 patients who were randomly assigned to receive these therapies or no treatment.
Researchers from the University of Birmingham conducted a trial finding that physiotherapy and occupational therapy do not improve 'activities of daily living' in patients with mild to moderate Parkinson's disease. The study suggests that resources should be reallocated towards more effective treatments.
Ongoing aerobic exercise has been shown to enhance factors that potentially have a protective effect on the brain, counteracting brain shrinkage and improving connections in individuals with Parkinson's disease. Aerobic exercise can also help manage symptoms such as rigid muscles, slowed movement, and impaired posture and balance.
Men with high urate levels have a lower risk of developing Parkinson's disease, according to a study published in Neurology. The study found that men with the highest urate levels were nearly 40% less likely to develop the disease.
A team of researchers at Boston University School of Medicine has discovered a previously unknown cellular defect in patients with idiopathic Parkinson's disease. The findings suggest that the cells' dysfunction of calcium homeostasis can determine whether certain neurons live or die.
A study published in The Lancet Neurology found that people with Parkinson's who took the oral drug rivastigmine were 45% less likely to fall and steadier when walking. This breakthrough treatment has the potential to improve quality of life for millions worldwide.
Researchers found an association between weight loss and rapid disease progression in Parkinson's patients. Those who lost weight showed a greater increase in symptoms, while those who gained weight had the smallest annual increase.
A clinical trial is underway to investigate the use of cholesterol-lowering drug Simvastatin in treating Parkinson's disease. The study, funded by several organizations, aims to explore its potential neuroprotective effects and could lead to new treatments for the condition.
Scientists successfully analyzed proteins in Lewy bodies of Parkinson's disease patients, revealing β sheet structures and lipid-rich cores that may lead to understanding disease formation. This breakthrough could aid development of epoch-making treatment for the progressive neurodegenerative disorder.
Researchers found that alpha-synuclein spreading in Parkinson's disease is triggered by enhanced expression and trans-neuronal passage of monomeric and oligomeric forms, rather than prion-like seeding. This new insight sheds light on the pathogenesis of Parkinson's disease.
A nationwide study in Taiwan found that people with hepatitis C virus were nearly 30% more likely to develop Parkinson's disease than those without. The study involved over 49,000 participants and followed them for an average of 12 years.
Researchers at Michigan Technological University have developed new probes to measure surface hydrophobicity in proteins. These sensors show significant improvements over existing commercial tools, with up to a 60-fold increase in detection strength.
Researchers used a portable device to compare brain activity in people with Parkinsonian syndromes and healthy adults. The study found that those with Parkinsonian symptoms demonstrated higher prefrontal cortex oxygenation levels to maintain stability while standing, and this difference relates to their performance in maintaining balance.
A team of researchers has identified a unique gait pattern among top Russian officials, including President Vladimir Putin and Prime Minister Dmitry Medvedev. The experts link this 'gunslinger's gait' to military or intelligence training, specifically KGB instruction on keeping the weapon close to the chest while walking.
Scientists at the University of Nottingham have discovered a small molecule called nicotinamide mononucleotide (NMN) that causes a chain reaction of destruction within neuron cell processes. This finding may lead to new therapies for age-related neurodegenerative disorders such as Parkinson's and Alzheimer's disease.
A study published in Neurology found an association between pesticide heptachlor epoxide and reduced brain cells in nonsmokers who drank more than two cups of milk daily. Researchers discovered residues of the pesticide in 90% of participants with high milk consumption, but note that the study does not show cause-and-effect.
Researchers at UC San Diego are investigating DNA methylation in the blood as a potential signature for Parkinson's disease. The study, funded by the Michael J. Fox Foundation, aims to improve early diagnosis and treatment of the chronic movement disorder.
Researchers at Case Western Reserve University School of Medicine received NIH grants to study Parkinson's disease, investigating gliptins for effective treatment. They also explored regenerating stem cells to heal the brain after a stroke and targeting brain tumor stem cells to develop new therapy strategies.
A study at Thomas Jefferson University has successfully increased the production of GM1 ganglioside in mice with Parkinson's disease. The researchers used an enzyme to convert naturally occurring ganglioside molecules into GM1, providing neuronal protection similar to direct GM1 injection.
Biologists at the University of York have created a reliable method to detect Parkinson's disease by analyzing fruit flies' visual responses. The study used adapted methods from human vision research and found increased neuronal activity in 'young' flies with Parkinson's mutations, leading to an 85% accurate classification rate.
Scientists measured dopamine signals in Parkinson's patients during brain surgery, revealing rapid dopamine release encodes information crucial for human choice. The findings have widespread implications for neurological and psychiatric disorders, including depression and addiction.
Researchers have uncovered a mechanism that helps repair damaged synapses, enabling optimal neuronal communication. This discovery highlights the importance of microautophagy in breaking down cellular debris and may lead to new treatments for neurodegenerative diseases like Alzheimer's.
A new approach has been discovered to reduce uncontrolled movements caused by levodopa, a common Parkinson's disease medication. By boosting the functioning of a specific brain receptor, scientists have found that side effects such as dyskinesia can be dramatically reduced.
A new diagnostic criteria for Parkinson's disease has been developed, aiming to improve diagnosis and treatment, especially in early stages. The criteria incorporate motor and non-motor symptoms, genetic factors, and propose a stage classification to focus on early detection.
Researchers have discovered a potential link between Parkinson's treatment and protection against age-related macular degeneration (AMD), the most common form of blindness. The study suggests that patients taking L-DOPA as Parkinson's treatment may be less likely to develop AMD, with delayed or prevented disease progression.
The article reviews lessons learned from Alzheimer's disease research to advance the development of screening and diagnostic algorithms for Parkinson's disease. It explores MCI-AD research, clinical trials incorporating biomarkers and genetics, and emerging therapeutic strategies targeting specific biological mechanisms.
A new study from Lund University suggests that unwanted blood vessel formation may be behind intractable walking and balance difficulties associated with Parkinson's disease. The researchers used cerebrospinal fluid samples from 100 patients and found clear connections between angiogenesis markers and symptoms.
Research reveals individual corals have varying capacities to adapt to changing ocean conditions brought about by climate change. The study found that some corals are more protective of their partner algae in harsh environmental conditions, suggesting a greater capacity to respond to climate change.
Researchers developed a method to deliver drugs across the blood-brain barrier using nasal mucosal grafting, showing neuroprotection in Parkinson's mouse models. The technique has potential to treat various brain disorders, including neurodegenerative diseases and psychiatric conditions.
Researchers at King's College London have identified a new gene, HIFalpha, that regulates nerve signals from damaged mitochondria in fruit flies. Switching off the HIFalpha gene restores nerve function and prevents early failure of nerve cells caused by mitochondrial damage.
A small phase I clinical trial found that an FDA-approved leukemia drug improved cognition, motor skills, and non-motor function in patients with Parkinson's disease and Lewy body dementia. The drug, nilotinib, also reduced toxic proteins linked to disease progression.
Researchers led by Assia Shisheva found a novel interaction partner of the ArPIKfyve-Sac3 complex in the brain, which binds Synphilin-1 and prevents its aggregation. This discovery may lead to new therapeutic approaches for reducing cytoplasmic aggregates in Parkinson's disease.
A new study found that people with Parkinson's disease psychosis who took antipsychotic medication were four times more likely to die than those who didn't. The treatment also led to serious health issues such as cognitive decline and worsening of Parkinson's symptoms.
A new study has found a potential treatment for Parkinson's disease by targeting specific nerve cells, showing promising results in rats. The technique could lead to less invasive and more precise treatment options for patients.
Scientists at UNC Eshelman School of Pharmacy created macrophages that deliver glial cell-derived neurotrophic factor (GDNF) and teach neurons to produce the protein. The treatment has shown promise in reversing Parkinson's disease progression and promoting neuron survival.
Researchers at Columbia University Irving Medical Center discovered that long-term use of L-DOPA leads to dyskinesia due to striatonigral neurons becoming less responsive to GABA. This suggests that modulating these neurons could prevent or delay dyskinesia.
Researchers found that external brain stimulation, specifically transcranial direct current stimulation (tDCS), can compensate for the loss of dopamine in people with Parkinson's disease by decreasing the effort the brain has to put into getting its motor neurons to fire. This correction improves some patients' motor symptoms.
Researchers at Massachusetts General Hospital found that urate stimulates astrocytes to activate an antioxidant pathway believed to have a role in several neurodegenerative disorders. A phase 3 trial of a urate-elevating drug, led by Dr. Michael Schwarzschild, is planned to enroll 270 patients with early-stage Parkinson's disease.
A new study published in Restorative Neurology and Neuroscience reports that repetitive transcranial magnetic stimulation can reduce gait freezing in Parkinson's patients. The treatment, involving high-frequency rTMS, improved motor skills and continued to show benefits even after the intervention was stopped.
Researchers have identified a new type of prion causing Multiple System Atrophy (MSA), a neurodegenerative disorder with similarities to Parkinson's disease. The discovery raises concerns about treatments and research involving contact with brain tissue from MSA patients.
Brain cells in Parkinson's disease are vulnerable due to high energy consumption, which can lead to exhaustion and cell death. This discovery may lead to new treatment strategies for reducing energy consumption or improving energy production in neurons.
Protein misfolding diseases are rising in incidence and seeing increasing financial and healthcare burden. Recent advances in understanding these disorders provide fresh ideas for their future therapy.
Researchers at Rockefeller University have identified two proteins, SATB1 and ZDHHC2, that appear to protect neurons from degeneration in Parkinson's disease. These proteins were found to be more abundant in dopamine-producing neurons in the substantia nigra pars compacta region, which is less affected by the disease.
Researchers discover UDCA, a decades-used liver treatment, may slow Parkinson's disease progression by rescuing damaged mitochondria. Studies confirm beneficial effects on nerve cells and genetic animal models of the condition.
Researchers at Scripps Research Institute will explore therapeutic potential of proteins regulating human health and associated diseases like Parkinson's and arthritis.
Researchers found that low-dose lithium reduced involuntary motor movements in Parkinson's disease mice, boosting dopamine synthesis via inhibition of calpain-1. This study adds to evidence that low-doses of the psychotropic drug could benefit patients suffering from the incurable condition.
A new study published in PLOS Medicine suggests that taking diabetes medication glitazones may lower the risk of developing Parkinson's disease by 28%. Researchers analyzed data from over 160,000 diabetes patients and found a significant association between glitazone use and reduced incidence of Parkinson's.
Researchers found that activating Nurr1, a class of proteins in the brain, protects dopamine neurons and improves motor control. The study suggests that existing anti-malaria drugs could be repurposed to treat Parkinson's disease.